Insmed (INSM) Interest Coverage Ratio Growth (1y) (2012 - 2026)
Powered by 
Analysis
Insmed (INSM) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 36.43% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -532.04% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -60.78% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -176.09% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1,170.12% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 99.48% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 67.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 99.48% |
| Mar 31, 2026 | 33.64% |
| Dec 31, 2025 | -45.18% |
| Sep 30, 2025 | -77.14% |
| Jun 30, 2025 | -8.41% |
| Mar 31, 2025 | -66.37% |
| Dec 31, 2024 | -24.65% |
| Sep 30, 2024 | -39.27% |
| Jun 30, 2024 | -18.92% |
| Mar 31, 2024 | 6.64% |
| Dec 31, 2023 | 6.88% |
| Sep 30, 2023 | 80.89% |
| Jun 30, 2023 | 56.58% |
| Mar 31, 2023 | 72.87% |
| Dec 31, 2022 | -5.52% |
| Sep 30, 2022 | -313.31% |
| Jun 30, 2022 | -206.52% |
| Mar 31, 2022 | -146.13% |
| Dec 31, 2021 | 30.76% |
| Sep 30, 2021 | -17.76% |